Angela Yoo1, Cerise Tang2, Mark Zucker3, Kelly Fitzgerald4, Renzo G DiNatale5, Phillip M Rappold6, Kate Weiss6, Benjamin Freeman5, Chung-Han Lee4, Nikolaus Schultz7, Robert Motzer4, Paul Russo6, Jonathan Coleman6, Victor E Reuter8, Ying-Bei Chen8, Maria I Carlo4, Anthony J Gill9, Ritesh R Kotecha10, A Ari Hakimi11, Ed Reznik12. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; SUNY Downstate Health Sciences University, Brooklyn, NY, USA; Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Physiology, Biophysics and Systems Biology Graduate Program, Weill Cornell Medicine, New York, NY, USA. 3. Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. Sydney Medical School, University of Sydney, Sydney, Australia; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St. Leonards, Australia; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St. Leonards, Australia. 10. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: kotechar@mskcc.org. 11. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hakimia@mskcc.org. 12. Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: reznike@mskcc.org.
Abstract
BACKGROUND: Succinate dehydrogenase-deficient and fumarate hydratase-deficient renal cell carcinomas (SDHRCC and FHRCC) are rare kidney cancers driven by loss of TCA cycle enzymes. OBJECTIVE: To define and compare the genomic and metabolomic hallmarks of SDHRCC and FHRCC. DESIGN, SETTING, AND PARTICIPANTS: We analyzed SDHRCC and FHRCC tumors with either immunohistochemical evidence of loss of protein expression or genomically confirmed biallelic inactivation of SDHA/B/C/D/AF2 or FH. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Somatic alterations were identified using clinical pipelines, with allele-specific copy number alterations (CNAs) identified using FACETS. Mass spectrometry-based metabolomic profiling was performed on available SDHRCC and FHRCC tumors. RESULTS AND LIMITATIONS: Tumors were analyzed for 42 patients (25 FHRCC, 17 SDHRCC). In the germline analysis, 16/17 SDHRCCs harbored a germline alteration in SDHB, whereas only 17/22 FHRCCs had pathogenic germline FH variants. SDHRCCs had a lower mutation burden (p = 0.02) and CNA burden (p = 0.0002) than FHRCCs. All SDHRCCs presented with deletion of chromosome 1p (overlapping SDHB), whereas FHRCCs demonstrated high but not ubiquitous loss of 1q (FH locus). Both SDHRCCs and FHRCCs exhibited significant idiopathic accumulation of the metabolite guanine. FHRCC tumors had elevated levels of urea cycle metabolites (argininosuccinate, citrulline, and fumarate), whereas SDHRCC tumors had elevation of numerous acylcarnitines. These characteristic metabolic changes allowed identification of a previously unrecognized SDH-deficient RCC. CONCLUSIONS: Despite sharing similar genetic etiology, SDHRCC and FHRCC represent distinct molecular entities with unique genetic and metabolic abnormalities. PATIENT SUMMARY: Kidney cancers driven by loss of the gene encoding either the succinate dehydrogenase or fumarate hydratase enzyme are rare. We sought to define and compare the genetic and metabolic features of these cancer entities.
BACKGROUND: Succinate dehydrogenase-deficient and fumarate hydratase-deficient renal cell carcinomas (SDHRCC and FHRCC) are rare kidney cancers driven by loss of TCA cycle enzymes. OBJECTIVE: To define and compare the genomic and metabolomic hallmarks of SDHRCC and FHRCC. DESIGN, SETTING, AND PARTICIPANTS: We analyzed SDHRCC and FHRCC tumors with either immunohistochemical evidence of loss of protein expression or genomically confirmed biallelic inactivation of SDHA/B/C/D/AF2 or FH. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Somatic alterations were identified using clinical pipelines, with allele-specific copy number alterations (CNAs) identified using FACETS. Mass spectrometry-based metabolomic profiling was performed on available SDHRCC and FHRCC tumors. RESULTS AND LIMITATIONS: Tumors were analyzed for 42 patients (25 FHRCC, 17 SDHRCC). In the germline analysis, 16/17 SDHRCCs harbored a germline alteration in SDHB, whereas only 17/22 FHRCCs had pathogenic germline FH variants. SDHRCCs had a lower mutation burden (p = 0.02) and CNA burden (p = 0.0002) than FHRCCs. All SDHRCCs presented with deletion of chromosome 1p (overlapping SDHB), whereas FHRCCs demonstrated high but not ubiquitous loss of 1q (FH locus). Both SDHRCCs and FHRCCs exhibited significant idiopathic accumulation of the metabolite guanine. FHRCC tumors had elevated levels of urea cycle metabolites (argininosuccinate, citrulline, and fumarate), whereas SDHRCC tumors had elevation of numerous acylcarnitines. These characteristic metabolic changes allowed identification of a previously unrecognized SDH-deficient RCC. CONCLUSIONS: Despite sharing similar genetic etiology, SDHRCC and FHRCC represent distinct molecular entities with unique genetic and metabolic abnormalities. PATIENT SUMMARY: Kidney cancers driven by loss of the gene encoding either the succinate dehydrogenase or fumarate hydratase enzyme are rare. We sought to define and compare the genetic and metabolic features of these cancer entities.
Authors: Mary A Selak; Sean M Armour; Elaine D MacKenzie; Houda Boulahbel; David G Watson; Kyle D Mansfield; Yi Pan; M Celeste Simon; Craig B Thompson; Eyal Gottlieb Journal: Cancer Cell Date: 2005-01 Impact factor: 31.743
Authors: Jennifer S Isaacs; Yun Jin Jung; David R Mole; Sunmin Lee; Carlos Torres-Cabala; Yuen-Li Chung; Maria Merino; Jane Trepel; Berton Zbar; Jorge Toro; Peter J Ratcliffe; W Marston Linehan; Len Neckers Journal: Cancer Cell Date: 2005-08 Impact factor: 31.743
Authors: Philip Jonsson; Chaitanya Bandlamudi; Michael L Cheng; Preethi Srinivasan; Shweta S Chavan; Noah D Friedman; Ezra Y Rosen; Allison L Richards; Nancy Bouvier; S Duygu Selcuklu; Craig M Bielski; Wassim Abida; Diana Mandelker; Ozge Birsoy; Liying Zhang; Ahmet Zehir; Mark T A Donoghue; José Baselga; Kenneth Offit; Howard I Scher; Eileen M O'Reilly; Zsofia K Stadler; Nikolaus Schultz; Nicholas D Socci; Agnes Viale; Marc Ladanyi; Mark E Robson; David M Hyman; Michael F Berger; David B Solit; Barry S Taylor Journal: Nature Date: 2019-07-10 Impact factor: 49.962
Authors: Jack P Gleeson; Ines Nikolovski; Renzo Dinatale; Mark Zucker; Andrea Knezevic; Sujata Patil; Yasser Ged; Ritesh R Kotecha; Natalie Shapnik; Samuel Murray; Paul Russo; Jonathan Coleman; Chung Han Lee; Zsofia K Stadler; A Ari Hakimi; Darren R Feldman; Robert J Motzer; Ed Reznik; Martin H Voss; Ying-Bei Chen; Maria I Carlo Journal: Clin Cancer Res Date: 2021-03-03 Impact factor: 12.531
Authors: Ying-Bei Chen; Jianing Xu; Anders Jacobsen Skanderup; Yiyu Dong; A Rose Brannon; Lu Wang; Helen H Won; Patricia I Wang; Gouri J Nanjangud; Achim A Jungbluth; Wei Li; Virginia Ojeda; A Ari Hakimi; Martin H Voss; Nikolaus Schultz; Robert J Motzer; Paul Russo; Emily H Cheng; Filippo G Giancotti; William Lee; Michael F Berger; Satish K Tickoo; Victor E Reuter; James J Hsieh Journal: Nat Commun Date: 2016-10-07 Impact factor: 14.919